隴神戎發(300534.SZ)2019年度淨利潤升4.07%至1277.75萬元 擬10派0.1元
格隆匯4月8日丨隴神戎發(300534.SZ)披露2019年年度報告,實現營業收入2.39億元,同比增17.64%;歸屬於上市公司股東的淨利潤1277.75萬元,同比增長4.07%,歸屬於上市公司股東的扣除非經常性損益的淨利潤543.55萬元,同比下降33.37%;基本每股收益0.0421元,擬每10股派發現金紅利0.1元(含税)。
公司從事的主要業務為醫藥產品、醫療產品、保健衞生產品的研究開發;中成藥、保健食品、原料藥的生產和銷售。目前共有滴丸劑、片劑、硬膠囊劑、膜劑4種劑型。主要產品元胡止痛滴丸、酸棗仁油滴丸、鞣酸小檗鹼膜和七味温陽膠囊均為獨家品種,3種藥品被列入《國家基本藥物目錄(2018年版)》,4種藥品被列入OTC甲類品種,5種藥品被列入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2019版)。
公司主打產品元胡止痛滴丸為國家重點新產品,具有理氣、活血、止痛的明確功效,產品劑型先進、效力持久、副作用小,綠色安全、服用方便,對於治療行經腹痛、胃痛、脅痛和頭痛療效顯著,為無成癮性的純中藥全科用藥,臨牀應用廣泛,特別適合於治療中度及慢性疼痛;既可單獨作為止痛類藥品使用,也可做輔助類藥品綜合組方用藥。在患者和醫生中認可度較高,雖然其止痛效果較化學藥止痛藥緩慢,但由於其“標本兼治”以及副作用小的優點,在多種慢性病痛症領域增長迅速,是國家醫保甲類藥品,連續入選2009年、2012年、2018年國家基藥目錄,在中藥止痛類藥物中佔據了一席之地,主要銷售於醫院終端。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.